Literature DB >> 26823295

Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.

Sarah J Cousins1, Seyed Ramin Radfar2, Desirée Crèvecoeur-MacPhail3, Alfonso Ang3, Kendall Darfler3, Richard A Rawson3.   

Abstract

Extended-release naltrexone (XR-NTX) is associated with an increased number of opioid-free days, improved adherence rates in substance use disorder treatment programs, and reduced cravings and drug-seeking behaviors. There is little evidence on the predictive associations between baseline characteristics of opioid-dependent patients and XR-NTX utilization. Some studies have demonstrated better pharmacotherapy adherence and/or retention rates among non-heroin opioid users compared to heroin users. This study examines predictive associations between characteristics of patients and XR-NTX utilization, as well as participants' urge to use opiates. Our findings suggest that XR-NTX may contribute to decreases in urges to use among both heroin and non-heroin opioid users. Non-heroin opioid users and heroin users were retained in XR-NTX treatment for comparable periods of time. However, those who identified as homeless, injected opioids (regardless of opioid-type), or were diagnosed with a mental illness were less likely to be retained in treatment with XR-NTX.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extended-release naltrexone; Heroin; Medication-assisted treatment; Opioid use disorder; Opioids

Mesh:

Substances:

Year:  2015        PMID: 26823295     DOI: 10.1016/j.jsat.2015.12.004

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  12 in total

1.  Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Iuliia Makarenko; Alyona Mazhnaya; Alexei Zelenev; Maxim Polonsky; Lynn Madden; Sergii Filippovych; Sergii Dvoriak; Sandra A Springer; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2017-08-05       Impact factor: 4.492

2.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Authors:  Marc R Larochelle; Dana Bernson; Thomas Land; Thomas J Stopka; Na Wang; Ziming Xuan; Sarah M Bagley; Jane M Liebschutz; Alexander Y Walley
Journal:  Ann Intern Med       Date:  2018-06-19       Impact factor: 25.391

3.  Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.

Authors:  Arthur Robin Williams; Vincent Barbieri; Kaitlyn Mishlen; Frances R Levin; Edward V Nunes; John J Mariani; Adam Bisaga
Journal:  Am J Addict       Date:  2017-03-22

4.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.

Authors:  Jake R Morgan; Bruce R Schackman; Jared A Leff; Benjamin P Linas; Alexander Y Walley
Journal:  J Subst Abuse Treat       Date:  2017-07-03

Review 5.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

6.  Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.

Authors:  Iuliia Makarenko; Iryna Pykalo; Sandra A Springer; Alyona Mazhnaya; Ruthanne Marcus; Sergii Filippovich; Sergii Dvoriak; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2019-05-10

7.  A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Martha J Bojko; Alyona Mazhnaya; Iuliia Makarenko; Sergii Filippovych; Sergii Dvoriak; Frederick L Altice; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2018-01-05

8.  Addiction consultation services - Linking hospitalized patients to outpatient addiction treatment.

Authors:  Paul Trowbridge; Zoe M Weinstein; Todd Kerensky; Payel Roy; Danny Regan; Jeffrey H Samet; Alexander Y Walley
Journal:  J Subst Abuse Treat       Date:  2017-05-11

9.  Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation.

Authors:  Uma M Reddy; Jonathan M Davis; Zhaoxia Ren; Michael F Greene
Journal:  Obstet Gynecol       Date:  2017-07       Impact factor: 7.623

Review 10.  Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Authors:  Virginia Perez-Macia; Mireia Martinez-Cortes; Jesus Mesones; Manuel Segura-Trepichio; Lorena Garcia-Fernandez
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.